Paper42111069
Myasthenia gravis complicated with autoimmune encephalitis: a review.
Gilhus NE. Front Neurol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Myasthenia gravis complicated with autoimmune encephalitis: a review. Papers, record 42111069. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42111069
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38421083 | Thymoma-associated autoimmune encephalitis with myasthenia gravis: Case series and literature review. | CNS Neurosci Ther | 2024 | https://conductscience.org/library/papers/38421083 | PubMed |
| 2 | 35060089 | Antibody Therapies in Autoimmune Encephalitis. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/35060089 | PubMed |
| 3 | 40755087 | Efgartigimod as a Fast-Acting Add-On Therapy in Antibody-Mediated Autoimmune Encephalitis. | Eur J Neurol | 2025 | https://conductscience.org/library/papers/40755087 | PubMed |
| 4 | 32312871 | Central nervous system complications associated with immune checkpoint inhibitors. | J Neurol Neurosurg Psychiatry | 2020 | https://conductscience.org/library/papers/32312871 | PubMed |
| 5 | 40557161 | Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40557161 | PubMed |
| 6 | 38967883 | Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion. | Neurol Sci | 2024 | https://conductscience.org/library/papers/38967883 | PubMed |
| 7 | 41743715 | Case Report: Thymoma-associated myasthenia gravis, myositis, myocarditis, and anti-GAD65 autoimmune encephalitis: a unique case of paraneoplastic polyautoimmunity. | Front Immunol | 2026 | https://conductscience.org/library/papers/41743715 | PubMed |
| 8 | 38101905 | Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. | Lancet Neurol | 2024 | https://conductscience.org/library/papers/38101905 | PubMed |
| 9 | 38152089 | Guideline for the management of myasthenic syndromes. | Ther Adv Neurol Disord | 2023 | https://conductscience.org/library/papers/38152089 | PubMed |
| 10 | 39845831 | Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39845831 | PubMed |
| 11 | 40242666 | Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors. | JTO Clin Res Rep | 2025 | https://conductscience.org/library/papers/40242666 | PubMed |
| 12 | 41317518 | Experience of bortezomib use in refractory autoimmune neurological disorders. | Mult Scler Relat Disord | 2026 | https://conductscience.org/library/papers/41317518 | PubMed |
| 13 | 40301313 | Immunotherapy for autoimmune encephalitis. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40301313 | PubMed |
| 14 | 33013323 | The Structure, Function, and Physiology of the Fetal and Adult Acetylcholine Receptor in Muscle. | Front Mol Neurosci | 2020 | https://conductscience.org/library/papers/33013323 | PubMed |
| 15 | 31982129 | A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases. | J Thorac Cardiovasc Surg | 2020 | https://conductscience.org/library/papers/31982129 | PubMed |
| 16 | 33329350 | Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management. | Front Neurol | 2020 | https://conductscience.org/library/papers/33329350 | PubMed |
| 17 | 35065040 | Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. | Lancet Neurol | 2022 | https://conductscience.org/library/papers/35065040 | PubMed |
| 18 | 25354676 | Myasthenia gravis and risks for comorbidity. | Eur J Neurol | 2015 | https://conductscience.org/library/papers/25354676 | PubMed |
| 19 | 34163474 | Next-Generation Sequencing Identifies Extended HLA Class I and II Haplotypes Associated With Early-Onset and Late-Onset Myasthenia Gravis in Italian, Norwegian, and Swedish Populations. | Front Immunol | 2021 | https://conductscience.org/library/papers/34163474 | PubMed |
| 20 | 37900608 | Case report: Seropositive myasthenia gravis complicated by limbic encephalitis positive for antibodies to AMPAR and Lgi1. | Front Neurol | 2023 | https://conductscience.org/library/papers/37900608 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FCGRT | 2217 | PubTator's text mining | https://conductscience.org/library/genes/2217 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42111069
GET https://conductscience.org/api/papers/v1/42111069/references?page=2